Clinical and sociodemographic characterization of long COVID-19 inCosta Rica
DOI:
https://doi.org/10.51481/amc.v67i2.1464Keywords:
coronavirus infections, risk factors, demography, signs and symptomsAbstract
Aim: to describe the clinical and sociodemographic profile of adults in Costa Rica who contracted Severe Acute Respiratory Syndrome Coronavirus type 2 and experienced symptoms for three months or longer after the acute phase of infection—classified as long COVID—and to compare them with adults without persistent symptoms, in order to identify factors linked to symptom persistence.
Methods: We carried out a retrospective descriptive study of Costa Rican adults recruited between January and October 2022. Eligibility required a laboratory-confirmed infection by Severe Acute Respiratory Syndrome Coronavirus type 2 at least three months before enrolment, documented by polymerase chain reaction, rapid antigen assay, or antibodybased test. Participants with compatible symptoms and an epidemiological link but no prior confirmation underwent serological testing for antibodies. An online questionnaire gathered demographic data, medical history, vaccination status, and symptoms. Based on these data, participants were classified as (1) individuals with symptoms lasting three months or longer (long COVID, strict phenotype) or (2) controls without prolonged symptoms; those reporting only nonspecific symptoms were excluded.
Results: among 448 participants, 193 met criteria for the strict long COVID phenotype, 198 served as controls, and 57 were excluded as indeterminate. The cohort was predominantly female (61.1 %) and younger than forty years (73.9 %). Most had a single documented infection (67.3 %), and 56.5 % reported acute-phase symptoms that limited daily activities. Complete vaccination was recorded in 91 %. The likelihood of long COVID was higher in females (probability ratio = 2.33; p value less than 0.001), in adults forty years or older (probability ratio = 1.82; p value = 0.039), in those whose acute symptoms restricted daily
activities (probability ratio = 2.09; p value = 0.002), and in participants with mentalhealth disorders (probability ratio = 1.87; p value = 0.018). No associations emerged with
vaccination status, smoking, alcohol use, physical activity, or number of comorbidities. Fifty-seven percent of long COVID cases reported poorer health than before the infection.
Conclusion: these findings align with international reports and underscore the need for prospective studies—particularly those stratified by sex—to clarify the long-term consequences of long COVID. They also highlight the urgency of comprehensive health policies to mitigate its
impact on quality of life. This study provides the first snapshot of long COVID in Costa Rica and lays groundwork for future research on post-viral syndromes in this population.
Downloads
References
1. Torner N. El fin de la emergencia internacional de salud pública por el COVID-19: ¿y ahora qué? [The end of COVID-19 Public Health Emergency of International Concern (PHEIC): and now what?]. Vacunas. 2023; 24:164-165. DOI:10.1016/j.vacun.2023.05.002
2. Rahmati M, Udeh R, Kang J, Dolja-Gore X, McEvoy M, Kazemi A, et al. Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of Symptoms 3 Years Post-SARS-CoV-2 Infection. J Med Virol. 2025; 97:1-14. DOI:10.1002/jmv.70429
3. Alizadeh H, Sharifi A, Damanbagh S, Nazarnia H, Nazarnia M. Impacts of the COVID-19 pandemic on the social sphere and lessons for crisis management: a literature review. Nat Hazards Rev. 2023; 117:2139-2164. DOI:10.1007/s11069-023-05959-2
4. Bull-Otterson L. Post–COVID conditions among adult COVID-19 survivors aged 18–64 and ?65 years — United States, March 2020–November 2021. MMWR Morb Mortal Wkly Rep. 2022; 71:713–717. DOI:10.15585/mmwr.mm7121e1
5. Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022; 101:93–135. DOI:10.1016/j.bbi.2021.12.020
6. Demko ZO, Yu T, Mullapudi SK, Varela Heslin MG, Dorsey CA, Payton CB, et al. Two-Year Longitudinal Study Reveals That Long COVID Symptoms Peak and Quality of Life Nadirs at 6-12 Months Postinfection. Open Forum Infect Dis. 2024; 11:1-8. DOI:10.1093/ofid/ofae027
7. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. BMJ. 2020; 370:1-8. DOI:10.1136/bmj.m3026
8. Raveendran AV. Long COVID-19: challenges in the diagnosis and proposed diagnostic criteria. Diabetes Metab Syndr. 2021; 15:145–146. DOI:10.1016/j.dsx.2020.12.025
9. López A, Bernal MR, Gómez R. Síndrome de COVID-19 persistente. Una revisión narrativa. Rev Clin Esp (Barc). 2023; 222:241–245. DOI:10.1016/j.rce.2021.10.003
10. Iqbal FM, Lam K, Sounderajah V, Clarke JM, Ashrafian H, Darzi A. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EClinicalMedicine. 2021; 36:1-13. DOI:10.1016/j.eclinm.2021.100899
11. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181:271–280. DOI:10.1016/j.cell.2020.02.052
12. Lopes M, Silva PL, Cruz FF, Battaglini D, Robba C, Pelosi P, et al. Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies. Front Physiol. 2021; 12:1-23. DOI:10.3389/fpsyg.2021.593223
13. Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. 2023; 23:618–634. DOI:10.1038/s41577-023-00904-7
14. Mateu L, Tebe C, Loste C, Santos JR, Lladós G, López C, et al. Determinants of the onset and prognosis of the post-COVID-19 condition: a 2-year prospective observational cohort study. Lancet Reg Health Eur. 2023; 33:1-14. DOI:10.1016/j.lanepe.2023.100724
15. Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023; 623:139-148. DOI:10.1038/s41586-023-06651-y
16. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023; 21:133-146. DOI:10.1038/s41579-023-00896-0
17. Mizrahi B, Sudry T, Flaks-Manov N, Yehezkelli Y, Kalkstein N, Akiva P, et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023; 380:1-17. DOI: 10.1136/bmj-2022-072529
18. Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. Risk factors associated with post?COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med. 2023; 183:566-580. DOI: 10.1001/jamainternmed.2023.0750
19. Mayor N, Meza-Torres B, Okusi C, Delanerolle G, Chapman M, Wang W, et al. Developing a long COVID phenotype for postacute COVID-19 in a national primary care sentinel cohort: observational retrospective database analysis. JMIR Public Health Surveill. 2022; 8:1-16. DOI: 10.2196/36989
20. Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020; 81:e4-e6. DOI: 10.1016/j.jinf.2020.08.029
21. Munipalli B, Seim L, Dawson NL, Knight D, Dabrh AMA. Post-acute sequelae of COVID-19 (PASC): a meta-narrative review of pathophysiology, prevalence, and management. SN Compr Clin Med. 2022; 4:1-14. DOI:10.1007/s42399-022-01167-4
22. Izquierdo-Condoy JS, Fernandez-Naranjo R, Vasconez-González E, Cordovez S, Tello-De-la-Torre A, Paz C, et al. Long COVID at different altitudes: a countrywide epidemiological analysis. Int J Environ Res Public Health. 2022; 19:146-173. DOI:10.3390/ijerph192214673
23. Prieto MA, Prieto O, Castro HM. Covid prolongado: estudio de corte transversal. Rev Fac Cien Med Univ Nac Córdoba. 2021; 78:33-36. DOI:10.31053/1853.0605.v78.n1.32048
24. Spinicci M, Graziani L, Tilli M, Nkurunziza J, Vellere I, Borchi B, et al. Infection with SARS-CoV-2 variants is associated with different long COVID phenotypes. Viruses. 2022; 14:1-10. DOI:10.3390/v14112367
25. Shabnam S, Razieh C, Dambha-Miller H, Yates T, Gillies C, Chudasama YV, et al. Socioeconomic inequalities of Long COVID: a retrospective population-based cohort study in the United Kingdom. J R Soc Med. 2023; 116:263-273. DOI:10.1177/01410768231168377
26. Kim, D. A nationwide study of risk factors for long COVID and its economic and mental health consequences in the United States. Commun Med (Lond). 2025; 5:1-14. DOI: 10.1038/s43856-025-00759-0
27. Mahmoodi Z, Bahrami G, Shahrestanaki E, Seddighi H, Ghavidel N. Clinical and socio-demographic variables associated with long COVID-19: a cross-sectional study. Clin Nurs Res. 2023; 32:947-953. DOI:10.1177/10547738231177395
28. Smoking increases the risk of post-acute COVID-19 syndrome: Results from a French community-based survey. Tob Induc Dis. 2022; 20:1-10. DOI:10.18332/tid/150295
29. Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022; 28:1706-1714. Barthélémy H, Mougenot E, Duracinsky M, Salmon-Ceron D, Bonini J, Pérez F, et al.DOI:10.1038/s41591-022-01909-w
30. Strain WD, Sherwood O, Banerjee A, Van der Togt V, Hishmeh L, Rossman J. The impact of COVID vaccination on symptoms of long COVID: an international survey of people with lived experience of long COVID. Vaccines (Basel). 2022; 10:1-10. DOI:10.3390/vaccines10050652
31. Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network — United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020; 69:993-998. DOI: 10.15585/mmwr.mm6930e1
32. Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021; 27:258-263. DOI: 10.1016/j.cmi.2020.09.052
33. Perlis RH, Santillana M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, et al. Prevalence and correlates of long COVID
symptoms among US adults. JAMA Netw Open. 2022; 5:1-11. DOI:10.1001/jamanetworkopen.2022.38804
34. Anaya JM, Rojas M, Salinas ML, Rodríguez Y, Roa G, et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021; 20: 1-15. DOI:10.1016/j.autrev.2021.102947
35. Xiang J, Zheng H, Cai Y, Chen S, Wang Y, Chen Rl. Cumulative social disadvantage and its impact on long COVID: insights from a U.S. national survey. BMC Med. 2025; 23:1-12. DOI:10.1186/s12916-025-04039-5
36. Azambuja P, Bastos LSL, Batista-da-Silva AA, Ramos GV, Kurtz P, Dias CMC, et al. Prevalence, risk factors, and impact of long COVID in a socially vulnerable community in Brazil: a prospective cohort study. Lancet Reg Health Am. 2024; 37:1-11. DOI:10.1016/j.lana.2024.100839
37. Lukkahatai N, Rodney T, Ling C, Daniel B, Han HR. Long COVID in the context of social determinants of health. Front Public Health. 2023; 11:1-7. DOI:10.3389/fpubh.2023.1098443
38. Louie P, Wu C. Race, socioeconomic status, and long COVID. SAGE Open Med. 2024; 11:203-215. DOI:10.1177/23294965231215081
39. Heller O, Chun Y, Shapira S, Troen A, Shlomo Y, Acri M, et al. Prevalence of Long-COVID Among Low-Income and Marginalized Groups: Evidence from Israel. Int J Public Health. 2022; 67: 1-11. DOI:10.3389/ijph.2022.1605086
40. Herridge MS, Azoulay É. The COVID-19 continuum of illness. Lancet Respir Med. 2022; 10:630–631. DOI: 10.1016/S2213-2600(22)00219-3
41. Parotto M, Gyöngyösi M, Howe K, Myatra SN, Ranzani O, Shankar-Hari M, et al. Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. Lancet Respir Med. 2023; 11:739-754. DOI: 10.1016/S2213-2600(23)00239-4
42. Perumal R, Shunmugam L, Naidoo K, Abdool Karim SS, Wilkins D, Garzino-Demo A, et al. Long COVID: a review and proposed visualization of the complexity of long COVID. Front Immunol. 2023; 14:1-18. DOI:10.3389/fimmu.2023.1117464
43. Gerritzen IM, Brus IM, Spronk I, Biere-Rafi S, Polinder S, Haagsma JA, et al. Identification of post-COVID-19 condition phenotypes, and differences in health-related quality of life and healthcare use: a cluster analysis. Epidemiol Infect. 2023; 151:1-10. DOI: 10.1017/S0950268823001139
44. Kenny G, McCann K, O'Brien C, Savinelli S, Tinago W, Yousif O, et al. Identification of distinct Long COVID clinical phenotypes through cluster analysis of self-reported symptoms. Open Forum Infect Dis. 2022; 9:ofac060. DOI: 10.1-9/ofid/ofac060
45. Blankestijn JM, Abdel-Aziz MI, Baalbaki N, Bazdar S, Beekers RJHC, Bloemsma LD, et al. Long COVID exhibits clinically distinct phenotypes at 3-6 months post-SARS-CoV-2 infection: results from the P4O2 consortium. BMJ Open Respir Res. 2024; 11:1-9. DOI:10.1136/bmjresp-2023-001907
46. Dagliati A, Strasser ZH, Hossein Abad ZS, Klann JG, Wagholikar KB, Mesa R, et al. Characterization of long COVID temporal sub-phenotypes by distributed representation learning from electronic health record data: a cohort study. EClinicalMedicine. 2023; 64:1-14. DOI: 10.1016/j.eclinm.2023.102210
47. Kisiel MA, Lee S, Malmquist S, Rykatkin O, Holgert S, et al. Clustering analysis identified three long COVID phenotypes and their association with general health status and working ability. J Clin Med. 2023; 12:1-17. DOI: 10.3390/jcm12113617
48. Deer RR, Rock MA, Vasilevsky N, Carmody L, Rando H, Anzalone AJ, et al. Characterizing Long COVID: Deep Phenotype of a Complex Condition. EBioMedicine. 2021; 74:1-9. DOI:10.1016/j.ebiom.2021.103722
49. Costas-Vilanova I, Mosteiro-Migéns DG, Domínguez-Martís EM, Padín PÁ, Novio S. Manifestaciones clínicas, prevalencia, duración y factores de riesgo del "Long COVID": una revisión bibliográfica. Enfermedades emergentes. 2023; 22:90-98.
50. Villacis NDL, Montesinos CEF, González AFM, Garzón MDM. Prevalência e principais manifestações do long Covid: um desafio para a medicina atual. Brazilian Journal of Health Review. 2023; 6:4843-4863. DOI: 10.34119/bjhrv6n2-032
51. Del Carpio-Orantes L, Hernández DT, Méndez SG, Díaz JSS, Silva AA, Vargas RL. Caracterización clínico-epidemiológica de los pacientes con COVID persistente en México. Gac Med Mex. 2024; 160:144-151. DOI:10.24875/GMM.23000385
52. Montserrat-Capdevila J, Fornells-Barberà I, Roso-Llorach A, Olivares-Sanzo P, Romero-Gracia A, Ichart JX. Impacto de la COVID-19 en la salud mental de la población: estudio en atención primaria. Aten Primaria. 2024; 56:1-2. DOI:10.1016/j.aprim.2023.102813
53. Hu Y, Liu Y, Zheng H, Liu L. Risk Factors for Long COVID in Older Adults. Biomedicines. 2023; 11:1-15. DOI:10.3390/biomedicines11113002
54. Suárez DL, Pascual EV, Soravilla JR. Covid persistente y discapacidad. Semergen. 2024; 50:1-9. DOI:10.1016/j.semerg.2023.102189
55. Hernández CP. Encefalitis miálgica o síndrome de fatiga crónica, implicaciones en su abordaje en las unidades del dolor en la era post-COVID. Rev. Soc. Esp. Dolor. 2021; 28:250-251. DOI:10.20986/resed.2021.3960/2021
56. Hamlin RE, Pienkos SM, Chan L, Stabile MA, Pinedo K, Rao M, et al. Sex differences and immune correlates of Long Covid development, symptom persistence, and resolution. Sci Transl Med. 2024; 16:1-84. DOI:10.1126/scitranslmed.adr1032
57. Silva J, Iwasaki A. Sex differences in postacute infection syndromes. Sci Transl Med. 2024; 16. DOI:10.1126/scitranslmed.ado2102
58. Lippi G, Sanchis-Gomar F, Henry BM. COVID-19 and its long-term sequelae: what do we know in 2023? Pol Arch Intern Med. 2023; 133:1-7. DOI:10.20452/pamw.16402
59. Chiner-Vives E, Cordovilla-Pérez R, De la Rosa-Carrillo D, García-Clemente M, Alonso JLI, Otero R, et al. Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases. Arch Bronconeumol. 2022; 58:39-50. DOI:10.1016/j.arbres.2022.03.011
60. Gamero-De-Luna EJ, Sánchez-Jaén. Factores genéticos asociados a long COVID. Semergen. 2024; 50:1-12. DOI:10.1016/j.semerg.2023.102187
61. Ceban F, Kulzhabayeva D, Rodrigues NB, Di Vincenzo JD, Gill H, Subramaniapillai M, et al. COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis. Brain Behav Immun. 2023; 111:211-229. DOI: 10.1016/j.bbi.2023.03.022
62. Lippi G, Mattiuzzi C, Sanchis-Gomar F. Physical Activity, Long-COVID, and Inactivity: A Detrimental Endless Loop. J Phys Act Health. 2024; 21:420-422. DOI:10.1123/jpah.2024-0057
63. Wang S, Quan L, Chavarro JE, Slopen N, Kubzansky LD, et al. Associations of Depression, Anxiety, Worry, Perceived Stress, and Loneliness Prior to Infection With Risk of Post–COVID-19 Conditions. JAMA Psychiatry. 2022; 79:1081–1091. DOI:10.1001/jamapsychiatry.2022.2640
64. Wang HI, Doran T, Crooks MG, Khunti K, Heightman M, et al. Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England. J Infect. 2024; 89:1-8. DOI:10.1016/j.jinf.2024.106235
65. Greißel A, Schneider A, Donnachie E, Gerlach R, Tauscher M, Hapfelmeier A. Impact of pre-existing mental health diagnoses on development of post-COVID and related symptoms: a claims data-based cohort study. Sci Rep. 2024; 14:1-12. DOI:10.1038/s41598-024-52656-6
66. Zerón A. COVID-19 y las variantes pentágono. Revista ADM (1979). 2022; 79:248-250. DOI:10.35366/107958
67. Krishna B, Wills M, Sithole N. Long COVID: what is known and what gaps need to be addressed. Br Med Bull. 2023; 147:6-19. DOI:10.1093/bmb/ldad016
68. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022; 28:1461-1467. DOI:10.1038/s41591-022-01840-0
69. Monje M, Iwasaki A. The neurobiology of long COVID. Neuron. 2022; 110:3484-3496. DOI:10.1016/j.neuron.2022.10.006
70. Tíscar-González V, Sánchez-Gómez S, Lafuente Martínez A, Peña Serrano A, Twose López M, Díaz Alonso S, et al. Vivencias e impacto en la calidad de vida de personas con COVID persistente. Gac Sanit. 2023; 37:1-7. DOI:10.1016/j.gaceta.2022.102247
71. Barboza-Solis C, Fantin R, Hildesheim A, Pfeiffer R, Porras C, Butt J., et al. COVID-19 and long-term impact on symptoms and Health-Related Quality of Life in Costa Rica: the RESPIRA cohort study. BMC Infect Dis. 2024; 24:1-14. DOI:10.1186/s12879-024-09450-6
72. Talari K, Goyal M. Retrospective studies–utility and caveats. J R Coll Physicians Edinb. 2020; 50:398-402. DOI:10.4997/JRCPE.2020.409
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
